Table 1 Baseline demographic and clinical characteristics
SPN group, n = 20 | EN group, n = 40 | P-value | |
|---|---|---|---|
Demographics | |||
Age, y | 69.0 ± 14.3 | 69.4 ± 12,6 | 0.912 |
male, n (%) | 10(50) | 20(50) | > 0.99 |
Weight, kg | 66.7 ± 12.0 | 61.9 ± 11.3 | 0.134 |
Body-mass index, kg/m2 | 24.2 ± 3.6 | 23.1 ± 3.1 | 0.248 |
Vital signs | |||
Temperature, ℃ | 37.2(36.8, 37.7) | 37.1(36.8, 37.4) | 0.615 |
Oxygenation index | 253.7 ± 96.5 | 272.8 ± 119.0 | 0.537 |
Time from stroke onset to admission, h | 24(5, 24) | 10.5(6, 24) | 0.565 |
Illness severity on admission | |||
NIHSS | 20(17, 33.7) | 17(14, 25.5) | 0.116 |
GCS | 8(5.25, 10) | 9(7, 11) | 0.124 |
NRS 2002 | 3(3, 4) | 3 (3, 3) | 0.746 |
Complications | |||
Hypertension, n (%) | 13(65) | 28(70) | 0.695 |
Previous stroke, n (%) | 6(30) | 11(27.5) | 0.839 |
Diabetes, n (%) | 5(25) | 13(32.5) | 0.55 |
Coronary artery disease, n (%) | 8(40) | 12(30) | 0.439 |
Renal disease, n (%) | 1(5) | 3(7.5) | > 0.99 |
Pneumonia, n (%) | 6(30) | 6(15) | 0.304 |
Thrombolytic therapy, n (%) | 2(10) | 6(15) | 0.893 |
Endovascular therapy, n (%) | 11(55) | 22(55) | > 0.99 |
Laboratory tests | |||
Leukocyte, × 109 | 11.4(8.4, 15.0) | 9.5(7.6, 10.8) | 0.04 |
Neutrophil, × 109 | 10.2(6.9, 13.8) | 7.3(5.9, 8.9) | 0.008 |
Lymphocyte, × 109 | 0.63(0.48, 0.93) | 0.95(0.82, 1.57) | 0.001 |
Neutrophil/lymphocyte | 15.97(9.09, 21.89) | 7.12(4.78, 10.21) | 0.001 |
Procalcitonin, ng/ml | 0.14(0.03, 0.40) | 0.06(0.04, 0.11) | 0.075 |
Interleukin-6, pg/ml | 35.8(14.3, 77.9) | 19.1(11.3, 57.5) | 0.17 |
Albumin, g/L | 36.2(34.7, 42.6) | 38.2(35.6, 40.8) | 0.541 |
Prealbumin, g/L | 0.13(0.10,0.21) | 0.18(0.13, 0.21) | 0.237 |
Triglyceride, mmol/L | 0.69(0.53, 1.32) | 1.01(0.75, 1.43) | 0.115 |
Cholesterol, mmol/L | 4.07 ± 1.04 | 3.99 ± 1.17 | 0.824 |
HbA1C, % | 6.05(5.72, 6.52) | 5.9(5.45, 10.2) | 0.522 |
Creatinine, μmol/L | 64.5(50.7, 84.5) | 66.0(56.2, 98.7) | 0.342 |